Hepatitis C virus vaccines

Vaccines

Volumn , Issue , 2008, Pages 1187-1199

  Reali, Eva ^a   Houghton, Michael ^b   Abrignani, Sergio ^a  

^a INGM Via Francesco Sforza 28   (Italy)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58949098233     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3611-1.50051-9     Document Type: Chapter

References (174)

1. B Robertson, G Myers, C Howard, et al. (1998) Classification, nomenclature, database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 143 2493-2503.
2. P Simmonds (2000) Hepatitis C Virus Genotypes San Diego, CA: Academic Press
3. J McHutchison and M Fried (2003) Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin Liver Dis 7 149-161.
4. M Houghton (1996) Hepatitis C Viruses Philadelphia, PA: Lippincott-Raven
5. BD Lindenbach and CM Rice (2005) Unravelling hepatitis C virus replication from genome to function. Nature 436 933-938.
6. R Rijnbrand, PJ Bredenbeek, PC Haasnoot, et al. (2001) The influence of downstream protein-coding sequence on internal ribosome entry on hepatitis C virus and other flavivirus RNAs. RNA 7 585-597.
7. J Dubuisson (2000) Folding, assembly and subcellular localization of hepatitis C virus glycoproteins. Curr Top Microbiol Immunol 242 135-148.
8. J Dubuisson, HH Hsu, RC Cheung, et al. (1994) Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol 68 6147-6160.
9. M Hijikata, N Kato, Y Ootsuyama, et al. (1991) Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci U S A 88 5547-5551.
10. RR Spaete, D Alexander, ME Rugroden, et al. (1992) Characterization of the hepatitis C virus E2/NS1 gene product expressed in mammalian cells. Virology 188 819-830.
11. A Grakoui, C Wychowski, C Lin, et al. (1993) Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 67 1385-1395.
12. AD Branch, DD Stump, JA Gutierrez, et al. (2005) The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, others. Semin Liver Dis 25 105-117.
13. Z Xu, J Choi, W Lu and JH Ou (2003) Hepatitis C virus F protein is a short-lived protein associated with the endoplasmic reticulum. J Virol 77 1578-1583.
14. R Ralston, K Thudium, K Berger, et al. (1993) Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. J Virol 67 6753-6761.
15. P Hussy, H Langen, J Mous and H Jacobsen (1996) Hepatitis C virus core protein: carboxy-terminal boundaries of two processed species suggest cleavage by a signal peptide peptidase. Virology 224 93-104.
16. K Yasui, T Wakita, K Tsukiyama-Kohara, et al. (1998) The native form and maturation process of hepatitis C virus core protein. J Virol 72 6048-6055.
17. KE Reed and CM Rice (2000) Overview of hepatitis C virus genome structure, polyprotein processing, protein properties. Curr Top Microbiol Immunol 242 55-84.
18. Lindenbach BD, CMR Flaviviridae: the viruses and their replication, 2001.
19. AJ Weiner, MJ Brauer, J Rosenblatt, et al. (1991) Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 180 842-848.
20. N Kato, H Sekiya, Y Ootsuyama, et al. (1993) Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol 67 3923-3930.
21. P Farci, A Shimoda, A Coiana, et al. (2000) The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288 339-344.
22. DG Bowen and CM Walker (2005) Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med 201 1709-1714.
23. H Tokita, H Okamoto, H Iizuka, et al. (1998) The entire nucleotide sequences of three hepatitis C virus isolates in genetic groups 7–9 and comparison with those in the other eight genetic groups. J Gen Virol 79 1847-1857.
24. AJ Weiner, X Paliard, MJ Selby, et al. (2001) Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J Virol 75 7142-7148.
25. N Kato, Y Ootsuyama and H Sekiya (1994) Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection. J Virol 68 4776-4784.
26. P Farci, A Shimoda, D Wong, et al. (1996) Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A 93 15394-15399.
27. P Pileri, Y Uematsu, S Campagnoli, et al. (1998) Binding of hepatitis C virus to CD81. Science 282 938-941.
28. PY Lozach, A Amara, B Bartosch, et al. (2004) C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. J Biol Chem 279 32035-32045.
29. B Bartosch, G Verney, M Dreux, et al. (2005) An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 79 8217-8229.
30. T Wakita, T Pietschmann, T Kato, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11 791-796.
31. J Zhong, P Gastaminza, J Chung, et al. (2006) Persistent hepatitis C virus infection in vitro: co-evolution of virus and host. J Virol 11082-11093.
32. V Lohmann, F Korner, J Koch, et al. (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285 110-113.
33. R Bartenschlager (2006) Hepatitis C virus molecular clones: from cDNA to infectious virus particles in cell culture. Curr Opin Microbiol 9 416-422.
34. BD Lindenbach, P Meuleman, A Ploss, et al. (2006) Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A 103 3805-3809.
35. M Yi, RA Villanueva, DL Thomas, et al. (2006) Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A 103 2310-2315.
36. B Bartosch, J Bukh, JC Meunier, et al. (2003) In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A 100 14199-14204.
37. M Flint, C Logvinoff, CM Rice and JA McKeating (2004) Characterization of infectious retroviral pseudotype particles bearing hepatitis C virus glycoproteins. J Virol 78 6875-6882.
38. FV Chisari (2005) Unscrambling hepatitis C virus-host interactions. Nature 436 930-932.
39. DM Forton, P Karayiannis, N Mahmud, et al. (2004) Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, serum variants. J Virol 78 5170-5183.
40. S Deforges, A Evlashev, M Perret, et al. (2004) Expression of hepatitis C virus proteins in epithelial intestinal cells in vivo. J Gen Virol 85 2515-2523.
41. BS Anand and M Velez (2004) Assessment of correlation between serum titers of hepatitis C virus and severity of liver disease. World J Gastroenterol 10 2409-2411.
42. BD Lindenbach, MJ Evans, AJ Syder, et al. (2005) Complete replication of hepatitis C virus in cell culture. Science 309 623-626.
43. JA McKeating, LQ Zhang, C Logvinoff, et al. (2004) Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virol 78 8496-8505.
44. S Crotta, A Stilla, A Wack, et al. (2002) Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 195 35-41.
45. A Wack, E Soldaini, C Tseng, et al. (2001) Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. Eur J Immunol 31 166-175.
46. CT Tseng and G Klimpel (2002) Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 195 43-49.
47. E Soldaini, A Wack, U D'Oro, et al. (2003) T cell costimulation by the hepatitis C virus envelope protein E2 binding to CD81 is mediated by Lck. Eur J Immunol 32(3), 455-464.
48. S Levy, SC Todd and HT Maecker (1998) CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol 16 89-109.
49. D Rosa, G Saletti, E De Gregorio, et al. (2005) Activation of B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci U S A 102 18544-18549.
50. JH Hoofnagle (2002) Course and outcome of hepatitis C. Hepatology 36 S21–S29.
51. A Alberti, L Chemello and L Benvegnu (1999) Natural history of hepatitis C. J Hepatol 31(Suppl 1), 17-24.
52. HJ Alter and LB Seeff (2000) Recovery, persistence and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 20 17-35.
53. K Patel, AJ Muir and JG McHutchinson (2006) Diagnosis and treatment of chronic hepatitis infection. BMJ 332 1013-1017.
54. LB Seeff (2002) Natural history of chronic hepatitis. Hepatology 36 S35-S46.
55. JJ Feld and J Hoofmagle (2005) Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436 967-972.
56. D Sene, N Limal and P Cacoub (2004) Hepatitis C virus-associated extrahepatic manifestations: a review. Metab Brain Dis 19 357-381.
57. C Ferri, F Greco, G Longombardo, et al. (1991) Association between hepatitis C virus and mixed cryoglobulinemia [see comment]. Clin Exp Rheumatol 9 621-624.
58. C Usalan, Y Erdem, B Altun, et al. (1998) Rapidly progressive glomerulonephritis associated with hepatitis C virus infection. Clin Nephrol 49 129-131.
59. CM Meyers, LB Seeff, CO Stehman-Breen and JH Hoofnagle (2003) Hepatitis C and renal disease: an update. Am J Kidney Dis 42 631-657.
60. E Negri, D Little, M Boiocchi, et al. (2004) B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review. Int J Cancer 111 1-8.
61. G De Rosa, ML Gobbo, A De Renzo, et al. (1997) High prevalence of hepatitis C virus infection in patients with B-cell lymphoproliferative disorders in Italy. Am J Hematol 55 77-82.
62. Y Nagao and M Sata (2004) Hepatitis C virus and lichen planus. J Gastroenterol Hepatol 19 1101-1113.
63. N Tsukazaki, M Watanabe and H Irifune (1998) Porphyria cutanea tarda and hepatitis C virus infection. Br J Dermatol 138 1015-1017.
64. World, Health, Organization (1997) Hepatitis C. Weekly Epidemiol Rec 72 65-72.
65. F Ebeling (1998) Epidemiology of the hepatitis C virus. Vox Sang 74(Suppl 2), 143-146.
66. L Pagliaro, V Peri, C Linea, et al. (1999) Natural history of chronic hepatitis. C. Ital J Gastroenterol Hepatol 31 28-44.
67. MR Larzo and SG Poe (2006) Adverse consequences of tattoos and body piercings. Pediatr Ann 35
68. M Piazza, L Sagliocca, G Tosone, et al. (1997) Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch Intern Med 157 1537-1544.
69. RC Hershow, PT O'Driscoll, E Handelsman, et al. (2005) Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study. Clin Infect Dis 40 859-867.
70. AR Zanetti, E Tanzi, L Romano, et al. (1998) Multicenter trial on mother-to-infant transmission of GBV-C virus. The Lombardy Study Group on Vertical/Perinatal Hepatitis Viruses Transmission. J Med Virol 54 107-112.
71. AJ Weiner, MM Thaler, K Crawford, et al. (1993) A unique, predominant hepatitis C virus variant found in an infant born to a mother with multiple variants. J Virol 67 4365-4368.
72. J O'Leary and R Chung (2006) Management of hepatitis C virus coinfection in HIV-infected persons. AIDS Read 16 313-320.
73. G Missale, R Bertoni, V Lamonaca, et al. (1996) Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 706-714.
74. DG Bowen and MW Christopher (2005) Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436 946-952.
75. JT Gerlach, HM Diepolder, MC Jung, et al. (1999) Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 117 933-941.
76. S Cooper, AL Erickson, EJ Adams, et al. (1999) Analysis of a successful immune response against hepatitis C virus. Immunity 10 439-449.
77. HM Diepolder, R Zachoval, RM Hoffmann, et al. (1995) Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346 1006-1007.
78. MJ Koziel, DK Wong, D Dudley, et al. (1997) Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. J Infect Dis 176 859-866.
79. D Lavillette, Y Morice, G Germanidis, et al. (2005) Human serum facilitates hepatitis C virus infection, neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 79 6023-6034.
80. K Ishii, D Rosa, Y Watanabe, et al. (1998) High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology 28 1117-1120.
81. K Bjoro, SS Froland, Z Yun, et al. (1994) Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 331 1607-1611.
82. JM Christie, CJ Healey, J Watson, et al. (1997) Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up. Clin Exp Immunol 110 4-8.
83. RG Knodell, ME Conrad, AL Ginsberg and CJ Bell (1976) Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis. Lancet 1 557-561.
84. C Feray, M Gigou, D Samuel, et al. (1998) Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med 128 810-816.
85. K Krawczynski, MJ Alter, D Tankersley, et al. (1996) Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 173 822-828.
86. E Foy, K Li, RJ Sumpter, et al. (2005) Control of antiviral defenses thropugh hepatitis C virus distruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A 102 2986-2991.
87. K Li, E Foy, JC Ferreonn, et al. (2005) Immune evasion by hepatitis C virus NS3/4A protease mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 102 2992-2997.
88. AL Erickson, Y Kimura, S Igarashi, et al. (2001) The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15 883-895.
89. AJ Weiner, HM Geysen, C Christopherson, et al. (1992) Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A 89 3468-3472.
90. C Voisset, AO de Beeck, P Horellou, et al. (2006) High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry. J Gen Virol 87 2577-2581.
91. H Wedemeyer, XS He, M Nascimbeni, et al. (2002) Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 169 3447-3458.
92. N Semmo, CL Day, SM Ward, et al. (2005) Preferential loss of IL-2 secreting CD4+ T helper cells in chronic HCV infection. Hepatology 41 1019-1028.
93. SL Tsai, YF Liaw, MH Chen, et al. (1997) Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis. C virus chronicity Hepatology 25 449-458.
94. R Thimme, D Oldach, KM Chang, et al. (2001) Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194 1395-1406.
95. A Grakoui, NH Shoukry, DJ Woolard, et al. (2003) HCV persistence and immune evasion in the absence of memory T cell help. Science 302 659-662.
96. NH Shoukry, A Grakoui, M Houghton, et al. (2003) Memory CD8+ T cells are required for protection from persistent hepatitis virus infection. J Exp Med 197 1645-1655.
97. F Lechner, NH Gruener, S Urbani, et al. (2000) CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol 30 2479-2487.
98. F Lechner, DK Wong, PR Dunbar, et al. (2000) Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191 1499-1512.
99. SL Khakoo, CL Thio, MP Martin, et al. (2004) HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305 872-874.
100. SE Bassett, B Guerra, K Brasky, et al. (2001) Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 2001; 33 1479-1487.
101. ME Major, K Mihalik, M Puig, et al. (2002) Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol 76 6586-6595.
102. RE Lanford, B Guerra, D Chavez, et al. (2004) Cross-genotype immunity to hepatitis C virus. J Virol 78 1575-1581.
103. P Farci, HJ Alter, S Govindarajan, et al. (1992) Lack of protective immunity against reinfection with hepatitis C virus. Science 258 135-140.
104. P Farci, G Orgiana and RH Purcell (1995) Immunity elicited by hepatitis C virus. Clin Exp Rheumatol 13(Suppl 13), S9-S12.
105. AM Prince, B Brotman, DH Lee, et al. (1999) Significance of the anti-E2 response in self-limited and chronic hepatitis C virus infections in chimpanzees and in humans. J Infect Dis 180 987-991.
106. SH Mehta, A Cox, DR Hoover, et al. (2002) Protection against persistence of hepatitis C. Lancet 359 1478-1483.
107. NK Polakos, D Drane, J Cox, et al. (2001) Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. J Immunol 166 3589-3598.
108. K Watanabe, K Yoshioka, H Ito, et al. (1999) The hypervariable region 1 protein of hepatitis C virus broadly reactive with sera of patients with chronic hepatitis C has a similar amino acid sequence with the consensus sequence. Virology 264 153-158.
109. QL Choo, G Kuo and R Ralston (1994) Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A 91 1294-1298.
110. G Leroux-Roels, E Depla, F Hulstaert, et al. (2004) A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine 22 3080-3086.
111. SH Jeong, M Qiao, M Nascimbeni, et al. (2004) Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J Virol 78 6995-7003.
112. DT O'Hagan, M Singh, C Dong, et al. (2004) Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine 23 672-680.
113. C Rollier, E Depla, JA Drexhage, et al. (2004) Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J Virol 78 187-196.
114. P Pancholi, Q Liu, N Tricoche, et al. (2000) DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins. J Infect Dis 182 18-27.
115. S Perri, CE Greer, K Thudium, et al. (2003) An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol 77 10394-10403.
116. JD Abraham, N Himoudi, F Kien, et al. (2004) Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins. Vaccine 22 3917-3928.
117. C Brinster, M Chen, D Boucreux, et al. (2002) Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J Gen Virol 83 369-381.
118. T Wuest, GW Both, AM Prince, et al. (2004) Recombinant ovine atadenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice. Vaccine 22 2717-2721.
119. F Nevens, T Roskams, H Van Vlierberghe, et al. (2003) A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 38 1289-1296.
120. MJ Pearse and D Drane (2005) ISCOMATRIX adjuvant for antigen delivery. Adv Drug Deliv Rev 57 465-474.
121. A Franzusoff, RC Duke, TH King, et al. (2005) Yeasts encoding tumour antigens in cancer immunotherapy. Expert Opin Biol Ther 5 565-575.
122. M Houghton, QL Choo, G Kuo, et al. (1995) Prospects for prophylactic and therapeutic hepatitis C virus vaccines. Princess Takamatsu Symp 5 25 232-235.
123. D Rosa, S Campagnoli, C Moretto, et al. (1996) A quantitative test to estimate neutralizing antibodies to the hepatitis C virus. cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A 93 1759-1763.
124. M Houghton and S Abrignani (2005) Prospects for a vaccine against the hepatitis C virus. Nature 436 961-966.
125. M Esumi, T Rikihisa, S Nishimura, et al. (1999) Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees. Arch Virol 144 973-980.
126. M Puig, ME Major, K Mihalik and SM Feinstone (2004) Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine 22 991-1000.
127. TF Baumert, S Ito, DT Wong and TJ Liang (1998) Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J Virol 72 3827-3836.
128. M Lechmann, K Murata, J Satoi, et al. (2001) Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology 417-423.
129. R Roccasecca, A Folgori, BB Ercole, et al. (2001) Mimotopes of the hyper variable region 1 of the hepatitis C virus induce cross-reactive antibodies directed against discontinuous epitopes. Mol Immunol 38 485-492.
130. LG Nemchinov, TJ Liang, MM Rifaat, et al. (2000) Development of a plant-derived subunit vaccine candidate against hepatitis C virus. Arch Virol 145 2557-2573.
131. S Urbani, B Amadei, P Fisicaro, et al. (2006) Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology 44 126-139.
132. P Botarelli, MR Brunetto, MA Minutello, et al. (1993) T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 104 580-587.
133. PA Wentworth, A Sette, E Celis, et al. (1996) Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome. Int. Immunol 8 651-659.
134. N Acosta-Rivero, JC Alvarez-Obregon, A Musacchio, et al. (2002) In vitro self-assembled HCV core virus-like particles induce a strong antibody immune response in sheep. Biochem Biophys Res Commun 290 300-304.
135. M Kunkel, M Lorinczi, R Rijnbrand, et al. (2001) Self-assembly of nucleocapsid-like particles from recombinant hepatitis C virus core protein. J Virol 75 2119-2129.
136. JC Alvarez-Obregon, S Duenas-Carrera, C Valenzuela and JM Grillo (2001) A truncated HCV core protein elicits a potent immune response with a strong participation of cellular immunity components in mice. Vaccine 19 3940-3946.
137. V Lamonaca, G Missale, S Urbani, et al. (1999) Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development. Hepatology 30 1088-1098.
138. KM Chang, NH Gruener, S Southwood, et al. (1999) Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. J Immunol 162 1156-1164.
139. O Moriya, M Matsui, M Osorio, et al. (2001) Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells treated with an anthrax toxin fusion protein. Vaccine 20 789-796.
140. S Uno-Furuta, S Tamaki, Y Takebe, et al. (2001) Induction of virus-specific cytotoxic T lymphocytes by in vivo electric administration of peptides. Vaccine 19 2190-2196.
141. L Planelles, MC Thomas, C Alonso and MC Lopez (2001) DNA immunization with Trypanosoma cruzi HSP70 fused to the KMP11 protein elicits a cytotoxic and humoral immune response against the antigen and leads to protection. Infect Immun 69 6558-6563.
142. IP Hunziker, B Grabscheid, R Zurbriggen, et al. (2002) In vitro studies of core peptide-bearing immunopotentiating reconstituted influenza virosomes as a non-live prototype vaccine against hepatitis C virus. Int Immunol 14 615-626.
143. T Saito, GJ Sherman, K Kurokohchi, et al. (1997) Plasmid DNA-based immunization for hepatitis C virus structural proteins: Immune responses in mice. Gastroenterology 112 1321-1330.
144. V Tedeschi, T Akatsuka, JW Shih, et al. (1997) A specific antibody response to HCV E2 elicited in mice by intramuscular inoculation of plasmid DNA containing coding sequences for E2. Hepatology 459-462.
145. G Inchauspe, ME Major, I Nakano, et al. (1997) DNA vaccination for the induction of immune responses against hepatitis C virus proteins. Vaccine 15 853-856.
146. I Nakano, G Maertens, ME Major, et al. (1997) Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode. J Virol 71 7101-7109.
147. A Fournillier, E Depla and P Karayiannis (1999) Expression of noncovalent hepatitis C virus envelope E1–E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization. J Virol 73 7497-7504.
148. X Forns, SU Emerson, GJ Tobin, et al. (1999) DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface. Vaccine 17 1992-2002.
149. EJ Gordon, R Bhat, Q Liu, et al. (2000) Immune responses to hepatitis C virus structural and nonstructural proteins induced by plasmid DNA immunizations. J Infect Dis 181 42-50.
150. JM Heile, YL Fong, D Rosa, et al. (2000) Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates. J Virol 74 6885-6892.
151. MK Song, SW Lee, YS Suh, et al. (2000) Enhancement of immunoglobulin G2a and cytotoxic T lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice. J Virol 74 2920-2925.
152. X Forns and PJ Payette (2000) Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 32 618-625.
153. J Encke, J zu Putlitz, M Geissler and JR Wands (1998) Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. J Immunol 161 4917-4923.
154. JH Cho, SW Lee and YC Sung (1999) Enhanced cellular immunity to hepatitis C virus nonstructural proteins by codelivery of granulocyte macrophage-colony stimulating factor gene in intramuscular DNA immunization. Vaccine 17 1136-1144.
155. M Shirai, H Okada, M Nishioka, et al. (1994) An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol 3334-3342.
156. LM Lagging, K Meyer, D Hoft, et al. (1995) Immune responses to plasmid DNA encoding the hepatitis C virus core protein. J Virol 69 5859-5863.
157. K Tokushige, T Wakita, C Pachuk, et al. (1996) Expression and immune response to hepatitis C virus core DNA-based vaccine constructs. Hepatology 24 14-20.
158. M Geissler, A Gesien, K Tokushige and JR Wands (1997) Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine expressing plasmids. J Immunol 158 1231-1237.
159. K Moriya, H Yotsuyanagi, Y Shintani, et al. (1997) Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 78 1527-1531.
160. RB Ray, LM Lagging, K Meyer and R Ray (1996) Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J Virol 70 4438-4443.
161. RB Ray, R Steele, K Meyer and R Ray (1997) Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem 272 10983-10986.
162. M Matsumoto, TY Hsieh, N Zhu, et al. (1997) Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor. J Virol 71 1301-1309.
163. RB Ray, K Meyer and R Ray (1996) Suppression of apoptotic cell death by hepatitis C virus core protein. Virology 226 176-182.
164. RB Ray, LM Lagging, K Meyer, et al. (1995) Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Res 37 209-220.
165. M Okuda, K Li, MR Beard, et al. (2002) Mitochondrial injury, oxidative stress, antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122 366-375.
166. C Brinster, S Muguet, YC Lone, et al. (2001) Different hepatitis C virus nonstructural protein 3 (Ns3)-DNA expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope. Hepatology 34 1206-1217.
167. S Zucchelli, S Capone, E Fattori, et al. (2000) Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J Virol 74 11598-11607.
168. D O'Hagan, M Singh, M Ugozzoli, et al. (2001) Induction of potent immune responses by cationic microparticles with adsorbed HIV DNA vaccines. J Virol 75 9037-9043.
169. MJ Caulfield, S Wang, JG Smith, et al. (2002) Sustained peptide-specific gamma interferon T-cell response in rhesus macques immunized with human immunodeficiency virus gag DNA vaccines. J Virol 76 10038-10043.
170. CW Mandl, JH Aberle, SW Aberle, et al. (1998) In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model. Nat Med 4 1438-1440.
171. CA Siler, JP McGettigan, B Dietzschold, et al. (2002) Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology 292 24-34.
172. YR Seong, S Choi, JS Lim, et al. (2001) Immunogenicity of the E1E2 proteins of hepatitis C virus expressed by recombinant adenoviruses. Vaccine 19 2955-2964.
173. O Bruna-Romero, JJ Lasarte, G Wilkinson, et al. (1997) Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus. Hepatology 25 470-477.
174. H Wedemeyer, S Gagneten, A Davis, et al. (2001) Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model. Gastroenterology 121 1158-1166.